Association of Cyclin Dependent Kinase 10 and Transcription Factor 2 during Human Corneal Epithelial Wound Healing in vitro model.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 08 2019
14 08 2019
Historique:
received:
20
02
2019
accepted:
25
07
2019
entrez:
16
8
2019
pubmed:
16
8
2019
medline:
11
11
2020
Statut:
epublish
Résumé
Proper wound healing is dynamic in order to maintain the corneal integrity and transparency. Impaired or delayed corneal epithelial wound healing is one of the most frequently observed ocular defect and difficult to treat. Cyclin dependen kinase (cdk), a known cell cycle regulator, required for proper proliferating and migration of cell. We therefore investigated the role of cell cycle regulator cdk10, member of cdk family and its functional association with transcriptional factor (ETS2) at active phase of corneal epithelial cell migration. Our data showed that cdk10 was associated with ETS2, while its expression was upregulated at the active phase (18 hours) of cell migration and gradually decrease as the wound was completely closed. Topical treatment with anti-cdk10 and ETS2 antibodies delayed the wound closure time at higest concentration (10 µg/ml) compared to control. Further, our results also showed increased mRNA expression of cdk10 and ETS2 at active phase of migration at approximately 2 fold. Collectively, our data reveals that cdk10 and ETS2 efficiently involved during corneal wound healing. Further studies are warranted to better understand the mechanism and safety of topical cdk10 and ETS2 proteins in corneal epithelial wound-healing and its potential role for human disease treatment.
Identifiants
pubmed: 31413335
doi: 10.1038/s41598-019-48092-6
pii: 10.1038/s41598-019-48092-6
pmc: PMC6694192
doi:
Substances chimiques
ETS2 protein, human
0
Proto-Oncogene Protein c-ets-2
0
CDK10 protein, human
EC 2.7.11.22
Cyclin-Dependent Kinases
EC 2.7.11.22
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11802Commentaires et corrections
Type : ErratumIn
Références
Prog Mol Biol Transl Sci. 2015;134:61-71
pubmed: 26310149
Mol Cancer Res. 2002 Nov;1(1):12-24
pubmed: 12496365
Proteomics. 2007 Feb;7(3):463-8
pubmed: 17211826
Oncogene. 2001 Apr 5;20(15):1832-8
pubmed: 11313931
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3834-8
pubmed: 8170997
Oman J Ophthalmol. 2013 May;6(2):83-6
pubmed: 24082664
Prog Retin Eye Res. 2003 Mar;22(2):113-33
pubmed: 12604055
Oncol Rep. 2012 Apr;27(4):1266-76
pubmed: 22209942
Biochem Biophys Res Commun. 2000 Sep 16;276(1):271-7
pubmed: 11006117
Clin Exp Pharmacol Physiol. 2010 Jan;37(1):83-7
pubmed: 19566835
Mol Vis. 2013;19:319-32
pubmed: 23401660
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Oncotarget. 2017 Jul 25;8(30):50174-50186
pubmed: 28178678
Hum Mol Genet. 2003 Feb 1;12(3):247-55
pubmed: 12554679
Am J Hum Genet. 2017 Sep 7;101(3):391-403
pubmed: 28886341
Cancer Cell. 2008 Feb;13(2):91-104
pubmed: 18242510
Cancer Res. 1995 Sep 15;55(18):3992-5
pubmed: 7664269
Nature. 1996 Feb 8;379(6565):534-7
pubmed: 8596630
J Pak Med Assoc. 2018 Oct;68(10):1493-1495
pubmed: 30317348
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19525-30
pubmed: 24218572
Methods Mol Biol. 2015;1207:317-26
pubmed: 25253150
Methods Mol Biol. 2012;842:313-25
pubmed: 22259145
BMC Cancer. 2015 Jul 25;15:548
pubmed: 26209438
Gene. 2012 Apr 25;498(1):68-74
pubmed: 22326270
Nat Protoc. 2007;2(2):329-33
pubmed: 17406593
Mol Cancer Ther. 2017 Oct;16(10):2292-2303
pubmed: 28663269
J Cell Sci. 2004 Aug 15;117(Pt 18):4089-98
pubmed: 15280426
J Cell Biochem. 2006 Oct 15;99(3):978-85
pubmed: 16741970
Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4
pubmed: 388439
Eur J Biochem. 2000 Aug;267(15):4713-9
pubmed: 10903504
Nucleic Acids Res. 2009 Jan;37(Database issue):D412-6
pubmed: 18940858
J Cancer. 2017 Aug 25;8(15):2907-2914
pubmed: 28928881